Cnd Life Sciences, An Innovative Medical Diagnostics Company Pioneering The Detection, Visualization, And Quantification Of Protein Deposition In Cutaneous Nerve Fibers, Has Been Awarded A $3 Million Phase Ii Small Business Innovation Research (Sbir) Grant From The National Institute Of Neurological Disorders And Stroke (Ninds) Of The National Institutes Of Health (Nih). This Is The Third Nih Sbir Phase Ii Award For The Company To Study And Advance The Clinical Application Of The Syn-One Test, The Only Commercially Available Test That Uses Skin Biopsies To Help Clinicians Diagnose A Synucleinopathy, A Family Of Neurodegenerative Diseases That Includes Parkinson
